Core Laboratories (CLB) AI Stock Analysis

• Market Cap: $785.06M
• Dividend Yield: 0.31%
• Average Volume (3M): 611.75K
• Price to Earnings (P/E): 24.4
• Beta (1Y): 1.11
• Revenue Growth: -1.02%
• EPS Growth: 6.34%
• Country: US
• Employees: 3,400
• Sector: Energy
• Sector Strength: 52
• Industry: Oil & Gas Equipment & Services
• EPS (TTM): 0.22
• Shares Outstanding: 46,563,390
• 10 Day Avg. Volume: 770,723
• 30 Day Avg. Volume: 611,752
• PEG Ratio: -1.70
• Price to Book (P/B): 3.22
• Price to Sales (P/S): 1.55
• P/FCF Ratio: 18.72
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: 1.41
• Enterprise Value/Gross Profit: 8.23
• Enterprise Value/Ebitda: 9.98
• 1Y Price Target: $12.00
• Price Target Upside: -28.83% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 2

• Rating: 67 Neutral
• Price Target: $18.50 ▲(9.73% Upside)

Core Laboratories demonstrates solid financial performance with consistent revenue growth and effective leverage management. Technical indicators show strong momentum, though the stock appears overbought, suggesting caution. Valuation metrics indicate potential overvaluation, and while the earnings call provided positive insights, challenges remain. Overall, the stock is on a positive trajectory but faces near-term risks.

Positive Factors

Revenue Growth

The consistent revenue growth indicates strong demand for Core Laboratories' services, particularly in international regions, which supports long-term business sustainability and market expansion.

Improved Operating Margins

Improved operating margins reflect effective cost management and operational efficiency, enhancing profitability and providing a buffer against potential cost pressures.

Strategic Acquisition

The acquisition of Solintec expands Core Laboratories' footprint in Brazil, potentially opening new markets and enhancing service offerings, which can drive long-term growth.

Negative Factors

Decline in Product Sales

Declining product sales indicate challenges in the U.S. onshore market, which could impact revenue streams and necessitate strategic adjustments to maintain growth.

Geopolitical and Tariff Challenges

Geopolitical tensions and tariffs create uncertainty in commodity prices, affecting demand for Core Laboratories' services and potentially hindering growth in volatile markets.

Flat Year-over-Year Revenue

Flat year-over-year revenue growth suggests challenges in maintaining momentum, which could impact long-term financial performance if not addressed through strategic initiatives.

Core Laboratories Business Overview & Revenue Model

Company Description

Core Laboratories (CLB) is a leading provider of proprietary and patented reservoir description and production enhancement services for the oil and gas industry. The company operates primarily in two segments: Reservoir Description and Production Enhancement. Core Laboratories offers a range of services, including reservoir fluid analysis, formation evaluation, and enhanced oil recovery, which are critical for oil and gas companies to optimize production and increase recovery rates from their reservoirs.

How the Company Makes Money

Core Laboratories generates revenue through its core services in reservoir description and production enhancement. The company earns money by providing specialized analytical services and technologies that help oil and gas companies assess and improve the efficiency of their extraction processes. Key revenue streams include fees for laboratory services, consulting, and proprietary technologies. Additionally, Core Labs often engages in partnerships with major oil companies and research organizations, which can enhance its service offerings and lead to increased contract opportunities. The demand for its services is influenced by the activity levels in the oil and gas sector, particularly in exploration and production, making the company's earnings sensitive to oil prices and industry trends.

Core Laboratories Financial Statement Overview

Summary

Core Laboratories demonstrates financial resilience with a strong income statement and stable cash flow generation. The company is effectively managing its operational costs and generating consistent revenue growth. The balance sheet shows a balanced approach to leverage, although there is room for improvement in equity stability.

Income Statement

Core Laboratories shows a consistent improvement in its revenue and profitability. The gross profit margin and net profit margin are improving, indicating operational efficiency. Revenue growth has been steady with a positive trend over the years. The EBIT and EBITDA margins are healthy, reflecting the company's ability to manage its operational costs effectively.

Balance Sheet

The company's balance sheet is stable, with a favorable debt-to-equity ratio showing manageable leverage. The equity ratio indicates a solid financial foundation, but there has been fluctuation in stockholders' equity. The return on equity is positive and improving, highlighting effective use of equity to generate profits.

Cash Flow

The cash flow statement reflects good cash generation capacity, with consistent free cash flow and operating cash flow relative to net income. There is a positive trend in free cash flow growth, which supports future investments and debt management. The operating cash flow to net income ratio is strong, demonstrating efficient cash operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	517.50M	523.85M	509.79M	489.74M	470.25M	487.27M
Gross Profit	88.59M	88.37M	94.05M	78.92M	83.84M	91.63M
EBITDA	73.10M	73.27M	70.42M	58.69M	63.78M	-56.73M
Net Income	32.12M	31.40M	36.67M	19.45M	19.73M	-97.21M
Balance Sheet
Total Assets	591.36M	590.41M	586.39M	578.35M	580.85M	568.58M
Cash, Cash Equivalents and Short-Term Investments	25.63M	19.16M	15.12M	15.43M	17.70M	13.81M
Total Debt	41.52M	180.14M	215.38M	222.39M	250.26M	326.98M
Total Liabilities	313.97M	332.67M	356.59M	389.40M	419.85M	493.01M
Stockholders Equity	277.39M	251.99M	224.81M	184.26M	156.45M	71.51M
Cash Flow
Free Cash Flow	45.32M	43.36M	14.21M	14.74M	23.04M	45.99M
Operating Cash Flow	49.70M	56.39M	24.79M	24.96M	36.58M	57.87M
Investing Cash Flow	-2.04M	-6.39M	-6.65M	-3.86M	-10.22M	7.85M
Financing Cash Flow	-43.51M	-45.96M	-18.45M	-23.38M	-22.46M	-63.01M

Core Laboratories Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 16.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLB, the sentiment is Positive. The current price of 16.86 is above the 20-day moving average (MA) of 12.53, above the 50-day MA of 12.16, and above the 200-day MA of 13.17, indicating a bullish trend. The MACD of 0.91 indicates Negative momentum. The RSI at 77.18 is Negative, neither overbought nor oversold. The STOCH value of 93.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLB.

Core Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TTI	―	$1.04B	8.83	54.03%	―	-3.23%	1031.00%
FTK	―	$502.81M	36.70	15.85%	―	21.72%	98.73%
CLB	―	$785.06M	24.41	12.31%	0.31%	-1.02%	6.34%
Sector *	―	$15.17B	7.61	4.09%	5.20%	3.87%	-62.32%
PUMP	―	$656.04M	-4.93	-16.86%	―	-10.91%	-580.59%
OIS	―	$402.94M	58.95	0.95%	―	-12.15%	―
ACDC	―	$660.18M	―	-25.45%	―	-4.14%	-39.14%

Core Laboratories Corporate Events

Core Laboratories Reports Steady Q3 2025 Performance

Core Laboratories N.V. is a leading provider of proprietary and patented reservoir description and production enhancement services and products, primarily serving the oil and gas industry worldwide.

Core Laboratories N.V. Earnings Call: Growth Amid Challenges

Core Laboratories N.V. Earnings Call Reveals Mixed Performance Amid Growth and Challenges

Core Laboratories Announces Q3 2025 Financial Results

On October 22, 2025, Core Laboratories Inc. announced its third quarter 2025 financial results, highlighting a revenue of $134.5 million, which was up over 3% sequentially but flat year-over-year. The company reported an operating income of $20.9 million and a GAAP EPS of $0.30. Core Lab also completed the acquisition of Solintec, a Brazilian geological services provider, to enhance its capabilities in the South Atlantic Margin. The company repurchased 462,248 shares and declared a quarterly cash dividend, demonstrating its commitment to returning value to shareholders. Additionally, Core Lab’s leverage ratio improved to its lowest level in nine years, indicating strong financial health and strategic positioning for future growth.

The most recent analyst rating on (CLB) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Core Laboratories stock, see the CLB Stock Forecast page.